Low Vitamin D Levels and Genetic Polymorphism in the Vitamin D Receptor are Associated with Increased Risk of Statin-Induced Myopathy

Basic and Clinical Pharmacology and Toxicology

Volumn 118, Issue 3, 2016, Pages 214-218

  Ovesjö, Marie Louise ^a   Skilving, Ilona ^a   Bergman, Peter ^a   Rane, Anders ^a   Ekström, Lena ^a   Björkhem Bergman, Linda ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; ATORVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; VITAMIN D RECEPTOR; BIOLOGICAL MARKER; CALCITRIOL RECEPTOR; VITAMIN D;

ADULT; AGED; ALLELE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG INDUCED DISEASE; FEMALE; FOLLOW UP; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GROUPS BY AGE; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MYOPATHY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUESTIONNAIRE; RISK ASSESSMENT; STATIN INDUCED MYOPATHY; VITAMIN BLOOD LEVEL; BLOOD; CHEMICALLY INDUCED; COMPLICATION; GENETICS; GENOTYPING TECHNIQUE; MUSCLE DISEASE; RISK FACTOR; VERY ELDERLY; VITAMIN D DEFICIENCY;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; BIOMARKERS; FEMALE; FOLLOW-UP STUDIES; GENOTYPING TECHNIQUES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; MUSCULAR DISEASES; OBSERVATIONAL STUDIES AS TOPIC; POLYMORPHISM, GENETIC; RECEPTORS, CALCITRIOL; RISK FACTORS; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 84983167658     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/bcpt.12482     Document Type: Article

References (36)

1. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90, 056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78.
2. Joy TR, Hegele RA. Narrative review: statin-related myopathy. Ann Intern Med 2009;150:858-68.
3. Magni P, Macchi C, Morlotti B, Sirtori CR, Ruscica M. Risk identification and possible countermeasures for muscle adverse effects during statin therapy. Eur J Intern Med 2015;26:82-8.
4. Soininen K, Niemi M, Kilkki E, Strandberg T, Kivisto KT. Muscle symptoms associated with statins: a series of twenty patients. Basic Clin Pharmacol Toxicol 2006;98:51-4.
5. Pojednic RM, Ceglia L, Olsson K, Gustafsson T, Lichtenstein AH, Dawson-Hughes B, Fielding RA. Effects of 1, 25-dihydroxyvitamin D and vitamin D on the expression of the vitamin D receptor in human skeletal muscle cells. Calcif Tissue Int 2014;96:256-63.
6. Carlberg C, Seuter S. A genomic perspective on vitamin D signaling. Anticancer Res 2009;29:3485-93.
7. Wang TT, Tavera-Mendoza LE, Laperriere D, Libby E, MacLeod NB, Nagai Y et al. Large-scale in silico and microarray-based identification of direct 1, 25-dihydroxyvitamin D3 target genes. Mol Endocrinol 2005;19:2685-95.
8. Holick MF. Vitamin D deficiency. N Engl J Med 2007;357:266-81.
9. Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton SK et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab 2011;96:53-8.
10. Hewison M. Antibacterial effects of vitamin D. Nat Rev Endocrinol 2011;7:337-45.
11. Wrzosek M, Lukaszkiewicz J, Wrzosek M, Jakubczyk A, Matsumoto H, Piatkiewicz P et al. Vitamin D and the central nervous system. Pharmacol Rep 2013;65:271-8.
12. Menezes AR, Lamb MC, Lavie CJ, DiNicolantonio JJ. Vitamin D and atherosclerosis. Curr Opin Cardiol 2014;29:571-7.
13. Wynn RL. Vitamin D deficiency and nonspecific musculoskeletal pain. Gen Dent 2013;61:10-3.
14. Jesus CA, Feder D, Peres MF. The role of vitamin D in pathophysiology and treatment of fibromyalgia. Curr Pain Headache Rep 2013;17:355.
15. Ceglia L, Niramitmahapanya S, da Silva Morais M, Rivas DA, Harris SS, Bischoff-Ferrari H et al. A randomized study on the effect of vitamin D(3) supplementation on skeletal muscle morphology and vitamin D receptor concentration in older women. J Clin Endocrinol Metab 2013;98:E1927-35.
16. McCarthy EK, Kiely M. Vitamin D and muscle strength throughout the life course: a review of epidemiological and intervention studies. J Hum Nutr Diet 2014. Epub ahead of print.
17. Mergenhagen K, Ott M, Heckman K, Rubin LM, Kellick K. Low vitamin D as a risk factor for the development of myalgia in patients taking high-dose simvastatin: a retrospective review. Clin Ther 2014;36:770-7.
18. Palamaner Subash Shantha G, Ramos J, Thomas-Hemak L, Pancholy SB. Association of vitamin D and incident statin induced myalgia-a retrospective cohort study. PLoS ONE 2014;9:e88877.
19. Ahmed W, Khan N, Glueck CJ, Pandey S, Wang P, Goldenberg N et al. Low serum 25 (OH) vitamin D levels (<32 ng/mL) are associated with reversible myositis-myalgia in statin-treated patients. Transl Res 2009;153:11-6.
20. Glueck CJ, Budhani SB, Masineni SS, Abuchaibe C, Khan N, Wang P et al. Vitamin D deficiency, myositis-myalgia, and reversible statin intolerance. Curr Med Res Opin 2011;27:1683-90.
21. Linde R, Peng L, Desai M, Feldman D. The role of vitamin D and SLCO1B1*5 gene polymorphism in statin-associated myalgias. Dermatoendocrinol 2010;2:77-84.
22. Eisen A, Lev E, Iakobishvilli Z, Porter A, Brosh D, Hasdai D et al. Low plasma vitamin D levels and muscle-related adverse effects in statin users. Isr Med Assoc J 2014;16:42-5.
23. Kurnik D, Hochman I, Vesterman-Landes J, Kenig T, Katzir I, Lomnicky Y et al. Muscle pain and serum creatine kinase are not associated with low serum 25(OH) vitamin D levels in patients receiving statins. Clin Endocrinol (Oxf) 2012;77:36-41.
24. Riphagen IJ, van der Veer E, Muskiet FA, DeJongste MJ. Myopathy during statin therapy in the daily practice of an outpatient cardiology clinic: prevalence, predictors and relation with vitamin D. Curr Med Res Opin 2012;28:1247-52.
25. Martineau AR, Timms PM, Bothamley GH, Hanifa Y, Islam K, Claxton AP et al. High-dose vitamin D(3) during intensive-phase antimicrobial treatment of pulmonary tuberculosis: a double-blind randomised controlled trial. Lancet 2011;377:242-50.
26. Selvaraj P, Chandra G, Jawahar MS, Rani MV, Rajeshwari DN, Narayanan PR. Regulatory role of vitamin D receptor gene variants of Bsm I, Apa I, Taq I, and Fok I polymorphisms on macrophage phagocytosis and lymphoproliferative response to mycobacterium tuberculosis antigen in pulmonary tuberculosis. J Clin Immunol 2004;24:523-32.
27. Betts S, Björkhem-Bergman L, Rane A, Ekström L. Expression of CYP3A4 and CYP3A7 in human fetal tissues and its correlation to nuclear receptors. Basic Clin Pharmacol Toxicol 2015;117:261-6.
28. Skilving I, Acimovic J, Rane A, Ovesjo ML, Bjorkhem-Bergman L. Statin-induced myopathy and ubiquinone levels in serum - results from a prospective, observational study. Basic Clin Pharmacol Toxicol 2015;117:133-6.
29. Pasternak RC, Smith SC Jr, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C et al. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol 2002;40:567-72.
30. Morioka TY, Lee AJ, Bertisch S, Buettner C. Vitamin D status modifies the association between statin use and musculoskeletal pain: a population based study. Atherosclerosis 2014;238:77-82.
31. Bergman P, Sperneder S, Hoijer J, Bergqvist J, Bjorkhem-Bergman L. Low vitamin d levels are associated with higher opioid dose in palliative cancer patients - results from an observational study in Sweden. PLoS ONE 2015;10:e0128223.
32. Wepner F, Scheuer R, Schuetz-Wieser B, Machacek P, Pieler-Bruha E, Cross HS et al. Effects of vitamin D on patients with fibromyalgia syndrome: a randomized placebo-controlled trial. Pain 2014;155:261-8.
33. Al-Daghri NM, Guerini FR, Al-Attas OS, Alokail MS, Alkharfy KM, Draz HM et al. Vitamin D receptor gene polymorphisms are associated with obesity and inflammosome activity. PLoS ONE 2014;9:e102141.
34. Morrison NA, Qi JC, Tokita A, Kelly PJ, Crofts L, Nguyen TV et al. Prediction of bone density from vitamin D receptor alleles. Nature 1994;367:284-7.
35. Lindh JD, Andersson ML, Eliasson E, Björkhem-Bergman L. Seasonal variation in blood drug concentrations and a potential relationship to vitamin D. Drug Metab Dispos 2011;39:933-7.
36. Virtanen JK, Nurmi T, Voutilainen S, Mursu J, Tuomainen TP. Association of serum 25-hydroxyvitamin D with the risk of death in a general older population in Finland. Eur J Nutr 2011;50:305-12.